Metabolic Drugs
345 FDA-approved drugs
TheraRadar tracks 345 FDA-approved metabolic drugs from 135 companies across 30 drug classes, led by Novo Nordisk, with 1,453 active clinical trials in the pipeline. Explore recent approvals, top companies, active trials by indication, and drug classes for Metabolic.
Metabolic Approvals by Year
10
'15
10
'16
14
'17
2
'18
15
'19
6
'20
9
'21
8
'22
10
'23
7
'24
9
'25
7
'26
Recent Metabolic Drug Approvals
CANAGLIFLOZIN
CANAGLIFLOZIN
2026-04-14
Novartis
DAPAGLIFLOZIN
DAPAGLIFLOZIN
Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adul...
2026-04-06
Novartis
SGLT2
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
DAPAGLIFLOZIN
Dapagliflozin and metformin HCl extended-release tablets are a combination of dapagliflozin and metf...
2026-04-06
Cipla
SGLT2
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE
DAPAGLIFLOZIN
Dapagliflozin and saxagliptin tablets are indicated as an adjunct to diet and exercise to improve gl...
2026-04-06
TORRENT
GLP-1GIPSGLT2
FOUNDAYO
ORFORGLIPRON CALCIUM
FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity ...
2026-04-01
Eli Lilly
GLP-1
AWIQLI FLEXTOUCH
INSULIN ICODEC
Awiqli is indicated as an adjunct to diet and exercise to improve glycemic control in adults with ty...
2026-03-26
Novo Nordisk
DESMODA
DESMOPRESSIN ACETATE
nephrogenic diabetes insipidus...
2026-02-25
ETON
SITAGLIPTIN PHOSPHATE
SITAGLIPTIN PHOSPHATE
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in ...
2025-12-29
Viatris
GLP-1GIPDPP-4
LEROCHOL
LERODALCIBEP-LIGA
LEROCHOL TM is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein choles...
2025-12-12
LIB THERAPEUTICS, INC.
PCSK9
REDEMPLO
PLOZASIRAN SODIUM
REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomic...
2025-11-18
ARROWHEAD
EYDENZELT
AFLIBERCEPT-BOAV
2025-10-02
CELLTRION
PlGFVEGF-A
KIRSTY
INSULIN ASPART-XJHZ
KIRSTY is indicated to improve glycemic control in adults and pediatric patients with diabetes melli...
2025-07-15
BIOCON BIOLOGICS INC
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
2025-06-04
Aurobindo Pharma
MERILOG
INSULIN ASPART-SZJJ
MERILOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mell...
2025-02-14
SANOFI-AVENTIS U.S. LLC
MERILOG SOLOSTAR
INSULIN ASPART-SZJJ
MERILOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mell...
2025-02-14
SANOFI-AVENTIS U.S. LLC
BRYNOVIN
SITAGLIPTIN HYDROCHLORIDE
1 INDICATIONS & USAGE BRYNOVIN is indicated as an adjunct to diet and exercise to improve glycemic c...
2025-01-16
AZURITY
GLP-1GIPDPP-4
LIRAGLUTIDE
LIRAGLUTIDE
Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control i...
2024-12-23
BIOCON PHARMA
GLP-1DPP-4
TRYNGOLZA (AUTOINJECTOR)
OLEZARSEN SODIUM
TRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomi...
2024-12-19
IONIS PHARMS INC
EXENATIDE SYNTHETIC
EXENATIDE SYNTHETIC
2024-11-19
AMNEAL
PAVBLU
AFLIBERCEPT-AYYH
patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1...
2024-08-23
Amgen
VEGFVEGF-AVEGFR
Showing the 20 most recent of 345 metabolic drugs. View all 345 →
Top Metabolic Companies
Metabolic Active Trials by Indication
1,453 active trials — the forward pipeline, not just approvals.
Obesity 524 Type 2 Diabetes 292 Diabetes (General) 194 Type 1 Diabetes 127 NASH/NAFLD 118 Diabetic Complications 108 Dyslipidemia 90
All competitive landscapes → Metabolic Drug Classes
Insulin Analog 24
Sodium-Glucose Cotransporter 2 Inhibitor 9
Dipeptidyl Peptidase 4 Inhibitor 9
GLP-1 Receptor Agonist 8
Sulfonylurea 8
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist 6
Alkaloid 5
Bile Acid Sequestrant 5
Vascular Endothelial Growth Factor Inhibitor 4
HMG-CoA Reductase Inhibitor 4
Metabolic at a Glance
- Total Drugs
- 345
- Companies
- 135
- Drug Classes
- 30
- Active Trials
- 1,453
- Latest Approval
- 2026-04-14